TECHNOLOGY LICENSING OPPORTUNITY: DC Recruiter
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
TRIAD - DOE CONTRACTOR
Contract Value
Not provided
Codes & Classification
Solicitation Number
S-195061
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AJ13
Additional Details
Documents1
Los Alamos National Laboratory (LANL), operating under the Department of Energy and managed by TRIAD as a DOE contractor, has issued a Special Notice regarding a technology licensing opportunity for "DC Recruiter," a broad-spectrum immune enhancer. This innovative platform, developed by LANL scientists, represents a differentiated approach to infection prevention by leveraging a self-assembling peptide nanofiber designed to recruit and activate dendritic cells (DCs)—the immune system’s natural sentinels. Unlike traditional pathogen-specific vaccines or therapeutics, DC Recruiter aims to trigger an early immune response regardless of the infecting agent, offering a practical, needle-free, spray-friendly administration format.
The primary purpose of this notice is to identify potential licensees interested in commercializing DC Recruiter. The technology addresses a critical gap in infection management: the need for rapid, broadly effective immune stimulation before the specific pathogen is identified. In scenarios where exposure occurs before diagnosis, conventional interventions may be delayed or ineffective. DC Recruiter’s platform is designed to “wake up” immune surveillance early, providing broad-spectrum support across diverse infectious threats. Its ease of administration and accessibility make it particularly suitable for outbreak situations, field environments, and other high-risk settings where rapid response is essential.
Key requirements and objectives for prospective licensees include the ability to advance the technology from its current development status (Technology Readiness Level 3) toward commercial applications. The expected deliverables involve further development, refinement, and market deployment of the DC Recruiter platform, potentially as a needle-free spray for broad-spectrum immune support. The technology is protected by a pending US patent (LA-UR-26-24915), and LANL offers both exclusive and non-exclusive licensing agreements to existing and start-up companies.
DC Recruiter’s advantages include:
- Accelerated immune response following exposure to infection
- Pathogen-agnostic mechanism, not limited to a single germ
- Targeting of dendritic cells to enhance immune system activation
- Utility in situations where the cause of infection is unknown
- Applicability in outbreak, emergency, and high-risk settings
- Needle-free, spray-friendly administration for ease of use
Market applications span infectious disease prevention, outbreak response, defense and national security, consumer health, pharmaceuticals and biotech, and emergency preparedness.
The contracting entity is TRIAD, a federal office under the Department of Energy, with the place of performance located in Los Alamos, New Mexico. The opportunity is classified under NAICS code 541714 (Research and Development in Biotechnology, except Nanobiotechnology) and Product Service Code AJ13. There are no set-aside requirements for this opportunity.
Interested parties are encouraged to contact Caleb Ledgerwood or Lindsay Augustyn at [email protected] for specific discussions regarding licensing. Additional information about LANL’s technology licensing program and available technologies can be found at https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology and m.lanl.gov/tech-search.
It is important to note that this notice is not a solicitation for external development services, but rather an invitation to license and commercialize the DC Recruiter technology. The opportunity remains active, with a response deadline of December 16, 2026. Contractors evaluating this opportunity should consider their capabilities in biotechnology R&D, immunomodulation, and commercial product development, as well as their interest in advancing a novel, broad-spectrum immune enhancer with significant real-world applications.